peoplePerson
Nirali N. Shah
Nirali Shah developed CD22 CAR-T for children whose leukaemia escaped CD19 therapy.
Leads paediatric CAR-T trials at NCI including the first CD22-directed CAR-T, addressing CD19-negative relapse after tisagenlecleucel and blinatumomab.
Role
Head, Hematologic Malignancies Section, Pediatric Oncology Branch
Institution
Specialisms
Paediatric leukaemiaCAR-TCD22
Profiles
| Title | Journal | Year |
|---|---|---|
| CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy | Nature Medicine | 2018 |